Stay updated on Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial

Sign up to get notified when there's something new on the Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a modification in the clinical trial study details related to the assessment of clinical benefit rate and survival outcomes in patients with melanoma brain metastasis undergoing immunotherapy with low dose ipilimumab and pembrolizumab.
    Difference
    0.1%
    Check dated 2024-06-06T14:17:38.000Z thumbnail image
  6. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change includes examples of eligibility criteria such as a person's general health condition or prior treatments, and provides a link for general information about clinical research.
    Difference
    52%
    Check dated 2024-05-22T21:01:08.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:28:44.000Z thumbnail image

Stay in the know with updates to Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial page.